VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor

P Vertongen; I Camby; F Darro; R Kiss; P Robberecht

doi:10.1016/s0143-4179(96)90015-3

VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor

Neuropeptides. 1996 Oct;30(5):491-6. doi: 10.1016/s0143-4179(96)90015-3.

Authors

P Vertongen¹, I Camby, F Darro, R Kiss, P Robberecht

Affiliation

¹ Laboratoire de Chimie Biologique et de la Nutrition, Université Libre de Bruxelles, Belgium.

PMID: 8923513
DOI: 10.1016/s0143-4179(96)90015-3

Abstract

Functional VIP/PACAP receptors were identified in the human glioblastoma cell line T98G, based on the relative potency of VIP, PACAP and PACAP-38 to stimulate adenylate cyclase activity. Analysis of the T98G cells mRNA by reverse transcription followed by a polymerase chain reaction (RT-PCR) demonstrated the expression of the mRNA coding for the VIP2 receptor subclass only. VIP, PACAP-27 and PACAP-38 were potent and efficIent inhibitors of cell proliferation, assessed by the colorimetric MTT assay. VIP, PACAP-27 and PACAP-38 also reduced the incorporation of 3H-thymidine in T98G cells, but did not significantly alter the percentage of cells present at each stage of the cell cycle. Thus, VIP and PACAP, probably acting through a VIP2 receptor subtype, decreased cell proliferation.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adenylyl Cyclases / metabolism*
Brain Neoplasms / pathology*
Cell Cycle / drug effects
Cell Division / drug effects
DNA Replication / drug effects
DNA, Neoplasm / biosynthesis
Enzyme Activation / drug effects
Glioblastoma / pathology*
Growth Inhibitors / pharmacology*
Humans
Neoplasm Proteins / drug effects*
Neoplasm Proteins / physiology
Neuropeptides / pharmacology*
Pituitary Adenylate Cyclase-Activating Polypeptide
Polymerase Chain Reaction
RNA, Messenger / biosynthesis
Receptors, Vasoactive Intestinal Peptide / drug effects*
Receptors, Vasoactive Intestinal Peptide / physiology
Receptors, Vasoactive Intestinal Peptide, Type II
Tumor Cells, Cultured / drug effects
Vasoactive Intestinal Peptide / pharmacology*

Substances

ADCYAP1 protein, human
DNA, Neoplasm
Growth Inhibitors
Neoplasm Proteins
Neuropeptides
Pituitary Adenylate Cyclase-Activating Polypeptide
RNA, Messenger
Receptors, Vasoactive Intestinal Peptide
Receptors, Vasoactive Intestinal Peptide, Type II
Vasoactive Intestinal Peptide
Adenylyl Cyclases